ADMA Biologics (NASDAQ:ADMA) Sets New 1-Year High at $20.28

Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) reached a new 52-week high on Monday . The stock traded as high as $20.28 and last traded at $20.19, with a volume of 1256695 shares. The stock had previously closed at $19.39.

Analysts Set New Price Targets

Several research firms have weighed in on ADMA. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a report on Friday, September 20th. Mizuho lifted their target price on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Finally, HC Wainwright lifted their target price on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, ADMA Biologics presently has an average rating of “Buy” and an average target price of $15.50.

ADMA Biologics Trading Up 2.5 %

The company has a market capitalization of $4.61 billion, a P/E ratio of -998.00 and a beta of 0.61. The business has a fifty day moving average price of $16.39 and a 200 day moving average price of $11.47. The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s quarterly revenue was up 78.4% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.02) earnings per share. On average, analysts expect that ADMA Biologics, Inc. will post 0.49 earnings per share for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the transaction, the director now owns 241,441 shares of the company’s stock, valued at $4,408,712.66. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is owned by insiders.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently bought and sold shares of the business. Quest Partners LLC acquired a new position in shares of ADMA Biologics in the second quarter valued at approximately $29,000. EntryPoint Capital LLC acquired a new position in shares of ADMA Biologics in the first quarter valued at about $31,000. CWM LLC increased its holdings in shares of ADMA Biologics by 114.2% during the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the period. Acadian Asset Management LLC acquired a new stake in ADMA Biologics during the second quarter worth approximately $93,000. Finally, Viewpoint Capital Management LLC increased its stake in ADMA Biologics by 18.6% during the 1st quarter. Viewpoint Capital Management LLC now owns 15,416 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 2,416 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.